Jimstan Periselneris

Author

King's College Hospital NHS Foundation Trust ORCID

Also Known As

J Periselneris, J. Periselneris, Jimstan N. Periselneris, Jimstan Periselneris, Periselneris, J

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

King's College Hospital NHS Foundation Trust University College London King's College London University of Oslo Royal Brompton & Harefield NHS Foundation Trust

About

Jimstan Periselneris is an author at King's College Hospital NHS Foundation Trust specializing in medicine, infection control, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	246
2	Public Health	3	3	142
3	Allergy	1	1	43
4	Emergency Medicine	1	1	11
5	Environmental Health	1	1	23

Jimstan Periselneris

Publications

953

Citations

H-Index

Page 1

	Year	Citations
Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia Rebecca D’Cruz, Michael D Waller, Felicity Perrin, ERJ Open Research	2020	182
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report Matthew Buckland, James Galloway, Caoimhe Nic Fhogartaigh, Nature Communications	2020	130
The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions Felix Chua, Darius Armstrong‐James, Sujal R. Desai, The Lancet Respiratory Medicine Covid-19 PandemicRespiratory InfectionInfectious Respiratory DiseaseHigh-incidence RegionsCovid-19 Epidemiology	2020	108
TLR-Mediated Inflammatory Responses to <i>Streptococcus pneumoniae</i> Are Highly Dependent on Surface Expression of Bacterial Lipoproteins Gillian S. Tomlinson, Suneeta Chimalapati, Tracey Pollard, The Journal of Immunology Inflammatory Lung DiseaseMicrobial PathogensLung InflammationInnate Immune SystemImmunology	2014	83
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders, The Lancet Infectious Diseases VaccinationCovid-19 PandemicVaccine TrialVirologyMolnupiravir Versus Placebo	2022	76
A Quorum-Sensing System That Regulates Streptococcus pneumoniae Biofilm Formation and Surface Polysaccharide Production Roger Junges, Gabriela Salvadori, Sudhanshu Shekhar, mSphere	2017	51
Exposure to welding fumes and lower airway infection with Streptococcus pneumoniae Reetika Suri, Jimstan Periselneris, Sophie Lanone, Journal of Allergy and Clinical Immunology Lower Airway InfectionStreptococcus PneumoniaeAllergyRespiratory ToxicologyRespiratory Diseases	2015	43
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial I’ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, Nature Communications	2022	42
Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis Jimstan Periselneris, Lisa Nwankwo, Silke Schelenz, Journal of Antimicrobial Chemotherapy	2019	37
Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort Katie Bechman, Mark Yates, Kirsty Mann, PLoS ONE	2022	35

Page 1